Quick Answer
GT Biopharma, Inc. reported Operating Income Loss of -$12.42 million for the year ending 2025.
- GT Biopharma, Inc. showed an increase of +13.5% in Operating Income Loss from 2024 to 2025.
- This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$1.81 million | Q2 2015: -$1.43 million | Q3 2015: -$2.78 million | Q1 2016: -$3.90 million | Q2 2016: -$2.12 million | Q3 2016: -$2.53 million | Q1 2017: -$1.54 million | Q2 2017: -$1.29 million | Q3 2017: -$126.86 million | Q1 2018: -$7.16 million | Q2 2018: -$5.16 million | Q3 2018: -$234.66 million | Q1 2019: -$4.06 million | Q2 2019: -$2.28 million | Q3 2019: -$8.86 million | Q1 2020: $1.07 million | Q2 2020: -$1.56 million | Q3 2020: -$1.95 million | Q1 2021: -$29.00 million | Q2 2021: -$4.38 million | Q3 2021: -$5.95 million | Q1 2022: -$5.44 million | Q2 2022: -$3.01 million | Q3 2022: -$7.02 million | Q1 2023: -$3.67 million | Q2 2023: -$3.62 million | Q3 2023: -$3.12 million | Q1 2024: -$3.09 million | Q2 2024: -$3.91 million | Q3 2024: -$3.60 million | Q1 2025: -$1.93 million | Q2 2025: -$1.51 million | Q3 2025: -$3.38 million.
- Over the full 16 years of available data (2010 to 2025), GT Biopharma, Inc.'s Operating Income Loss has declined by 397.5%.
- Historical annual values: Fiscal year 2025: -$12.42 million | Fiscal year 2024: -$14.36 million | Fiscal year 2023: -$13.58 million | Fiscal year 2022: -$21.26 million | Fiscal year 2021: -$57.52 million | Fiscal year 2020: -$6.76 million | Fiscal year 2019: $16.06 million | Fiscal year 2018: -$250.07 million | Fiscal year 2017: -$135.57 million | Fiscal year 2016: -$9.37 million | Fiscal year 2015: -$8.93 million | Fiscal year 2014: -$2.40 million | Fiscal year 2013: -$793.0 thousand | Fiscal year 2012: -$3.51 million | Fiscal year 2011: -$3.93 million | Fiscal year 2010: -$2.50 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: